| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4015 | Pbiilh2 | Pyridobenzimidazole infraluciferin, an analog of D-luciferin, increasing bioluminescence activity while maintaining nIR bioluminescence |
|
| DCC4016 | P-bi-tat | Novel αvβ3 inhibitor, showing excellent efficacy in a glioblastoma multiforme (GBM) mouse model |
|
| DCC4017 | Pbs-1086 | Novel dual inhibitor of the canonical and noncanonical NF-κB pathways, increasing the magnitude and duration of initial EGFR inhibitor response in multiple NSCLC models, decreasing PDHK1 expression, and suppressing phosphorylation of the PDHK1 protein sub |
|
| DCC4018 | Pb-wut-01 | Novel calcineurin inhibitor in the C. albicans cells, enhancing susceptibility of the cells |
|
| DCC4019 | pc-046 | Potent tubulin-binding agent with anti-tumor efficacy in hematologic cancers |
|
| DCC4020 | Pc407-ws | Water-soluble novel potential COX-2 inhibitor |
|
| DCC4021 | Pcb153 | Non-dioxin-like (NDL) congener |
|
| DCC4022 | Pcb-te2p | Novel Chelator for Cu-64 |
|
| DCC4023 | Pcc-0105002 | Novel PSD95-nNOS inhibitor, disrupting the PSD95-nNOS interaction, attenuating neuropathic pain, decreasing SNL-induced spinal dorsal horn WDR neuron hyperexcitation |
|
| DCC4024 | Pcc0208018 | Novel activator of effector T cells, enhancing T cell proliferation and activation to release interferon gamma (IFN-γ) and interleukin-2 (IL-2) without blocking the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) binding and not dire |
|
| DCC4025 | P-cf3-diepp | Novel α7 nAChR weak partial agonist, showing antinociceptive and anti-inflammatory properties |
|
| DCC4026 | p-chloro-diphenyl Diselenide | Organoselenium compound with antidepressant-like and memory enhancer actions |
|
| DCC4027 | pcm126 | Potent antagonist of the series disrupting EphA2-ephrinA1 interaction, blocking EphA2 phosphorylation in prostate cancer cells at low |
|
| DCC4028 | p-come 102 | Highly selective α1L adrenaline receptor agonist |
|
| DCC4029 | Pcpma-(1r,2r)-22e | Novel potent dopamine D3R agonist (Ki=4.1nM) |
|
| DCC4030 | Pcpma-(1r,2r)-30q | Novel potent and selective dopamine D3R partial agonist |
|
| DCC4031 | Pcpma-(1s,2s)-22e | Novel potent dopamine D3R antagonist |
|
| DCC4032 | Pcsk9 Modulator | Novel modulator of proprotein convertase subtilisin kexin like type 9 (PCSK9) |
|
| DCC4033 | Pcsk9-in-4d | Novel PCSK9 mRNA translation inhibitor |
|
| DCC4034 | Pcsk9-in-4g | Novel PCSK9 mRNA translation inhibitor |
|
| DCC4035 | Pcsk9-in-8b | Novel liver-targeted inhibitor of ribosomal synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
|
| DCC4036 | Pd-1 Inhibitor 16 | Novel inhibitor of PD-I/PD-L1 interaction to be used as a negative immune checkpoint regulatory and antineoplastic agent |
|
| DCC4037 | Pd-1/pd-l1 Antagonist D2 | Novel potent PD-1/PD-L1 antagonist (IC50 of 16.17 nM), activating the antitumor immunity of T cells efficiently in PBMCs |
|
| DCC4038 | Pd-1/pd-l1 Inhibitor 17 | Novel bifunctional inhibitor of PD-1/PD-L1 interactions, promoting dimerization, internalization, and degradation of PD-L1, suppressing tumor growth in vivo by activating antitumor immunity |
|
| DCC4039 | Pd-1/pd-l1 Inhibitor A30 | Novel Potent Inhibitor of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction |
|
| DCC4040 | Pd-1/pd-l1 Inhibitor Ch1 | Novel inhibitor of PD-1/PD-L1 (IC 50 value of 56.58 nM), dose-dependently promoting HepG2 cell death in a co-culture model of HepG2/hPD-L1 and Jurkat T cells, effectively inhibiting tumor growth (TGI of 76.4% at 90 mg/kg) in an immune checkpoint humanized |
|
| DCC4041 | Pd-1/pd-l1 Inhibitor P18 | Novel potent programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor (IC50 9.1 nM) |
|
| DCC4042 | Pd-128907 Hydrochloride | Selective D3 dopamine receptor agonist |
|
| DCC4043 | Pd-151242 | Selective antagonist for human ETA receptors |
|
| DCC4044 | Pd160170 | Neuropeptide Y Y1 receptor antagonist |
|
